Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 with RT and ADT for Prostate Cancer
NCT02472275Phase 1Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2015
- Primary completion
- Aug 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pexidartinib in prostate adenocarcinoma, sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoints: Grade of specific types of toxicity and Maximum Tolerated Dose at 4 months. Started Jun 2015; status: completed.
02
Drugs
pexidartinib
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT02472275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472275.